CA 15-3 and bone scintigraphy in the follow-up of breast cancer
- PMID: 9582604
- DOI: 10.1177/172460089701200403
CA 15-3 and bone scintigraphy in the follow-up of breast cancer
Abstract
By means of the retrospective study of the clinical records of 158 women followed for breast cancer, we aimed to evaluate the consequences of a non-systematic indication for bone scan (BS) based either on CA 15-3 levels alone or a combination of tumor marker levels and clinical criteria. With the first option, the negative predictive value was 95% and 82% of the BS would have been avoided. With the second option, the negative predictive value was 97% and 59% of the BS would have been avoided. Furthermore, the preliminary results of a longitudinal study showed that those patients with normal CA 15-3 levels and positive bone scans showed a subsequent rise in CA 15-3 levels which frequently became elevated with a average delay of 15 months. Omission of systematic bone scans in the follow-up of breast cancer patients is likely to lead to a delay in the diagnosis of bone metastasis in 3% to 5%, the consequences of which have to be examined carefully.
Similar articles
-
Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.Anticancer Res. 1997 May-Jun;17(3B):1683-6. Anticancer Res. 1997. PMID: 9179218
-
Relationship between bone scintigraphy and tumor markers in patients with breast cancer.Ann Nucl Med. 2004 Sep;18(6):501-5. doi: 10.1007/BF02984567. Ann Nucl Med. 2004. PMID: 15515750
-
The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.Br J Cancer. 1999 Mar;79(9-10):1443-7. doi: 10.1038/sj.bjc.6690230. Br J Cancer. 1999. PMID: 10188888 Free PMC article.
-
Reevaluaton of the usefulness of systematic bone scanning in initial staging and follow-up of small cell lung carcinoma, taking into account the serum levels of neuron-specific enolase.Int J Biol Markers. 1997 Oct-Dec;12(4):148-53. doi: 10.1177/172460089701200402. Int J Biol Markers. 1997. PMID: 9582603 Review.
-
Serum CA 15.3, CEA and ESR patterns in breast cancer.Int J Biol Markers. 1997 Oct-Dec;12(4):168-73. doi: 10.1177/172460089701200406. Int J Biol Markers. 1997. PMID: 9582607 Review.
Cited by
-
Current role of bone scan with phosphonates in the follow-up of breast cancer.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S143-8. doi: 10.1007/s00259-004-1537-6. Epub 2004 Apr 16. Eur J Nucl Med Mol Imaging. 2004. PMID: 15088128 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials